Home » Topics » BioWorld Science

BioWorld Science
RSS

Marker of neuroaxonal injury is also a marker of worse outcomes in COVID-19 patients

Aug. 12, 2021

Enrollment ongoing in phase II studies of ABBV-154

Aug. 12, 2021

Algernon Pharmaceuticals announces SCLC research program for ifenprodil

Aug. 12, 2021

JadiCell shows superior neurogenesis induction in model of viral-induced cognitive dysfunction

Aug. 12, 2021

Further data from phase I study of UV-1 in metastatic melanoma

Aug. 12, 2021

Cali Biosciences initiates MERIT-1 study of long-acting ropivacaine for postoperative pain

Aug. 12, 2021

Imatinib preserves Beta-cell function in subjects with type 1 diabetes

Aug. 12, 2021

FDA clears IND for XeriSol levothyroxine subcutaneous injection

Aug. 12, 2021

RemeGen completes phase II study of telitacicept in IgAN

Aug. 12, 2021

Lynk initiates dosing in phase I study of its triple-kinase inhibitor LNK-01002

Aug. 12, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...